SG Americas Securities LLC Sells 36,377 Shares of Geron Co. (NASDAQ:GERN)

SG Americas Securities LLC trimmed its stake in shares of Geron Co. (NASDAQ:GERN) by 68.1% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 17,071 shares of the biopharmaceutical company’s stock after selling 36,377 shares during the quarter. SG Americas Securities LLC’s holdings in Geron were worth $72,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of GERN. New York State Common Retirement Fund grew its stake in Geron by 14.0% during the fourth quarter. New York State Common Retirement Fund now owns 210,890 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 25,959 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Geron by 19.8% in the fourth quarter. Russell Investments Group Ltd. now owns 1,237,234 shares of the biopharmaceutical company’s stock valued at $2,611,000 after acquiring an additional 204,765 shares during the last quarter. Victory Capital Management Inc. raised its position in Geron by 28.1% during the fourth quarter. Victory Capital Management Inc. now owns 61,909 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 13,596 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Geron by 5.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,842,500 shares of the biopharmaceutical company’s stock valued at $8,108,000 after purchasing an additional 208,170 shares in the last quarter. Finally, Vivo Capital LLC increased its stake in shares of Geron by 46.1% in the 4th quarter. Vivo Capital LLC now owns 24,143,681 shares of the biopharmaceutical company’s stock valued at $50,943,000 after purchasing an additional 7,619,047 shares during the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Price Performance

Shares of NASDAQ:GERN opened at $4.66 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.67 and a current ratio of 3.67. Geron Co. has a 52 week low of $1.64 and a 52 week high of $5.34. The firm has a market cap of $2.76 billion, a PE ratio of -13.31 and a beta of 0.48. The firm’s fifty day moving average is $4.56 and its 200-day moving average is $3.74.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $0.88 million for the quarter, compared to the consensus estimate of $0.34 million. Geron had a negative return on equity of 68.16% and a negative net margin of 38,730.00%. The business’s quarterly revenue was up 2941.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.09) EPS. Sell-side analysts predict that Geron Co. will post -0.35 earnings per share for the current year.

Insider Buying and Selling

In other Geron news, EVP Faye Feller sold 287,900 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $4.63, for a total transaction of $1,332,977.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Geron news, COO Andrew J. Grethlein sold 674,348 shares of the stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $4.56, for a total transaction of $3,075,026.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Faye Feller sold 287,900 shares of Geron stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $4.63, for a total value of $1,332,977.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,562,248 shares of company stock valued at $6,808,004 over the last ninety days. 3.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on GERN shares. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Geron in a research report on Friday, August 9th. Stifel Nicolaus lifted their price target on shares of Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, June 10th. Robert W. Baird cut shares of Geron from an “outperform” rating to a “neutral” rating and set a $4.50 price objective for the company. in a research report on Tuesday, April 30th. StockNews.com upgraded shares of Geron to a “sell” rating in a research report on Monday, August 5th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Geron in a report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.07.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.